$PPCB
Propanc Biopharma Inc Stock $ppcb

$ppcb Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000114420415031499 Filed on May 15, 2015

Income Statement

Concept	2015 Q2	2015 Q1	2014 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$580.0K	$510.0K	$110.0K
YoY Change	427.27%	410.0%	-38.89%
% of Gross Profit
Research & Development	$120.0K	$9.475K	$10.00K
YoY Change	1100.0%		0.0%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$700.0K	$516.6K	$120.0K
YoY Change	483.33%	395.2%	-36.84%
Operating Profit		-$516.6K
YoY Change		395.2%
Interest Expense	-$1.130M	$199.3K	-$90.00K
YoY Change	1155.56%	901.39%	200.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	$62.32K
YoY Change		66.4%
Pretax Income	-$1.820M	-$454.3K	-$220.0K
YoY Change	727.27%	579.35%	0.0%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.830M	-$454.3K	-$220.0K
YoY Change	731.82%	579.35%	0.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$675.8M	-$281.4M	-$374.1M
COMMON SHARES
Basic Shares Outstanding	334.9M shares	191.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2015 Q1	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$110.0K	$170.0K	$90.00K
YoY Change	22.22%
Cash & Equivalents			$87.80K
Short-Term Investments
Other Short-Term Assets	$500.0K	$130.0K	$30.00K
YoY Change	1566.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$621.9K	$308.8K	$113.7K
YoY Change	446.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.494K	$808.00	$0.00
YoY Change			-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00
YoY Change
Total Long-Term Assets	$5.178K	$808.00	$0.00
YoY Change			-100.0%
TOTAL ASSETS
Total Short-Term Assets	$621.9K	$308.8K	$113.7K
Total Long-Term Assets	$5.178K	$808.00	$0.00
Total Assets	$627.1K	$309.6K	$113.7K
YoY Change	451.29%		6410.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$236.5K	$291.0K	$332.6K
YoY Change	-28.9%	-11.81%	22.0%
Accrued Expenses	$460.0K	$440.0K	$490.0K
YoY Change	-6.12%	2.33%	63.33%
Deferred Revenue
YoY Change
Short-Term Debt	$1.900M	$1.250M	$0.00
YoY Change		443.48%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.681M	$2.161M	$1.522M
YoY Change	141.82%	84.67%	92.67%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.681M	$2.161M	$1.522M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.680M	$2.160M	$1.520M
YoY Change	142.11%	84.62%	92.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$20.97M	-$19.14M	-$17.55M
YoY Change	19.44%
Common Stock	$347.4K	$332.8K	$72.69K
YoY Change	378.01%		2.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.054M	-$1.851M	-$1.408M
YoY Change
Total Liabilities & Shareholders Equity	$627.1K	$309.6K	$113.7K
YoY Change	451.29%		6410.88%

Cashflow Statement

Concept	2015 Q2	2015 Q1	2014 Q2
OPERATING ACTIVITIES
Net Income	-$1.830M	-$454.3K	-$220.0K
YoY Change	731.82%	579.35%	0.0%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change
Cash From Operating Activities	-$730.0K	-$430.0K	-$90.00K
YoY Change	711.11%	975.0%	200.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	-$10.00K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	600.0K	580.0K	170.0K
YoY Change	252.94%	1060.0%	466.67%
NET CHANGE
Cash From Operating Activities	-730.0K	-430.0K	-90.00K
Cash From Investing Activities	-10.00K	0.000
Cash From Financing Activities	600.0K	580.0K	170.0K
Net Change In Cash	-140.0K	150.0K	80.00K
YoY Change	-275.0%	1400.0%
FREE CASH FLOW
Cash From Operating Activities	-$730.0K	-$430.0K	-$90.00K
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$730.0K	-$430.0K
YoY Change		975.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	8217	USD
	dei	Document Type DocumentType	10-Q
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	PPCH
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	334915794	shares
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-598103	USD
	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	Propanc Health Group Corp
	dei	Entity Central Index Key EntityCentralIndexKey	0001517681
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent" align="justify"><u><font style="FONT-SIZE: 10pt">Use of Estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from these estimates.  Significant estimates in the accompanying unaudited consolidated financial statements include the estimates of valuation of derivatives, valuation of beneficial conversion features on convertible debt, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1	us-gaap	Cash Cash	168348	USD
CY2014Q2	us-gaap	Cash Cash	87799	USD
CY2015Q1	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	6332	USD
CY2014Q2	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	946	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	134136	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	25000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	308816	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	113745	USD
CY2015Q1	us-gaap	Assets Assets	309624	USD
CY2014Q2	us-gaap	Assets Assets	113745	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	291028	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	332564	USD
CY2015Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	0	USD
CY2014Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	17440	USD
CY2015Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	373503	USD
CY2014Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	422326	USD
CY2015Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1138184	USD
CY2014Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	272424	USD
CY2015Q1	us-gaap	Notes Payable Current NotesPayableCurrent	27680	USD
CY2014Q2	us-gaap	Notes Payable Current NotesPayableCurrent	33909	USD
CY2015Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	101384	USD
CY2014Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	0	USD
CY2015Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	44966	USD
CY2014Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	158244	USD
CY2015Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	35264	USD
CY2014Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	60350	USD
CY2015Q1	ppch	Loans From Related Party LoansFromRelatedParty	79769	USD
CY2014Q2	ppch	Loans From Related Party LoansFromRelatedParty	161975	USD
CY2015Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	68817	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15797	USD
CY2014Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	62827	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2160595	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1522059	USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue	5000	USD
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	332781	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	72685	USD
CY2015Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16903399	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16374781	USD
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	46933	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-302863	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19139084	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17552917	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	-1850971	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	-1408314	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	309624	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113745	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	349796	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-48009	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-79302	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-697541	USD
CY2015Q1	ppch	Working Capital Deficit WorkingCapitalDeficit	1851779	USD
CY2015Q1	ppch	Decrease In Liability Due To Director DecreaseInLiabilityDueToDirector	44000	USD
CY2014Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.0709
CY2014Q3	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	139680	USD
CY2014Q3	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	154798	USD
CY2014Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8161000	shares
CY2014Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4000000	shares
CY2014Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	2183333	shares
CY2013Q3	us-gaap	Accrued Rent Current And Noncurrent AccruedRentCurrentAndNoncurrent	1000	USD
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	15587000	shares
CY2015Q1	ppch	Sale Of Stock Decreased Liability Owed To Purchaser SaleOfStockDecreasedLiabilityOwedToPurchaser	52907	USD
CY2014Q3	us-gaap	Payments For Fees PaymentsForFees	50000	USD
CY2014Q3	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	50000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	405000	USD
CY2014Q3	us-gaap	Longterm Purchase Commitment Period LongtermPurchaseCommitmentPeriod	P24M
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	500000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	500000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	332780344	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72684767	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	332780344	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72684767	shares
CY2015Q1	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	101384	USD
CY2015Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	44966	USD
CY2015Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	146350	USD
CY2014Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	158244	USD
	us-gaap	Gain Loss On Foreign Currency Fair Value Hedge Derivatives GainLossOnForeignCurrencyFairValueHedgeDerivatives	19454	USD
	ppch	Fair Value Of Warrant Derivative Liability Recoreded As Debt Discount FairValueOfWarrantDerivativeLiabilityRecorededAsDebtDiscount	87500	USD
	ppch	Fair Value Of Warrant Derivative Liability Recoreded As Change In Fair Value Of Eco FairValueOfWarrantDerivativeLiabilityRecorededAsChangeInFairValueOfEco	985399	USD
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-1065339	USD
CY2015Q1	us-gaap	Share Price SharePrice	85000
CY2015Q1	us-gaap	Convertible Debt ConvertibleDebt	0.015	USD
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2015Q1	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	101626	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	504724	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	630121	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	980637	USD
CY2014Q1	us-gaap	Occupancy Costs OccupancyCosts	2689	USD
CY2015Q1	us-gaap	Occupancy Costs OccupancyCosts	2366	USD
	us-gaap	Occupancy Costs OccupancyCosts	8217	USD
	us-gaap	Occupancy Costs OccupancyCosts	7710	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9475	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	104315	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	516565	USD
	us-gaap	Operating Expenses OperatingExpenses	638338	USD
	us-gaap	Operating Expenses OperatingExpenses	1004144	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-104315	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-516565	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-638338	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1004144	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	19901	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	199287	USD
	us-gaap	Interest Expense InterestExpense	42291	USD
	us-gaap	Interest Expense InterestExpense	847942	USD
CY2014Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-47909	USD
CY2015Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	131659	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-32741	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	349796	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-114774	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-322591	USD
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	13	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	16	USD
CY2014Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
CY2015Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	50002	USD
CY2014Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	58650	USD
CY2015Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-42802	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	27016	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	79940	USD
CY2014Q1	us-gaap	Gain Loss On Repurchase Of Debt Instrument GainLossOnRepurchaseOfDebtInstrument	0	USD
CY2015Q1	us-gaap	Gain Loss On Repurchase Of Debt Instrument GainLossOnRepurchaseOfDebtInstrument	331457	USD
	us-gaap	Gain Loss On Repurchase Of Debt Instrument GainLossOnRepurchaseOfDebtInstrument	0	USD
	us-gaap	Gain Loss On Repurchase Of Debt Instrument GainLossOnRepurchaseOfDebtInstrument	366341	USD
CY2014Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-1299	USD
CY2015Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-27066	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-6373	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-209678	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	37450	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	62315	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-21648	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-661325	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-66865	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-454250	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-659986	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1665469	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-66865	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-454250	USD
	us-gaap	Net Income Loss NetIncomeLoss	-611977	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1586167	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-644718	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1236371	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.00
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.00
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	72684768	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	201772426	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	72234522	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	124223579	shares
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	237833	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	199727	USD
	us-gaap	Depreciation Depreciation	538	USD
	us-gaap	Depreciation Depreciation	18	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	30434	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	167535	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	0	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	5560	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1224	USD
CY2014Q1	us-gaap	Cash Cash	40	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	ppch	Conversion Of Convertible Notes And Accrued Interest To Common Stock ConversionOfConvertibleNotesAndAccruedInterestToCommonStock	0	USD
	ppch	Conversion Of Convertible Notes And Accrued Interest To Common Stock ConversionOfConvertibleNotesAndAccruedInterestToCommonStock	206940	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	ppch	Conversion Of Accrued Expenses To Common Stock ConversionOfAccruedExpensesToCommonStock	27500	USD
	ppch	Conversion Of Accrued Expenses To Common Stock ConversionOfAccruedExpensesToCommonStock	0	USD
	ppch	Discounts Related To Warrants Issued With Convertible Debenture DiscountsRelatedToWarrantsIssuedWithConvertibleDebenture	133095	USD
	ppch	Discounts Related To Warrants Issued With Convertible Debenture DiscountsRelatedToWarrantsIssuedWithConvertibleDebenture	0	USD
	ppch	Discounts Related To Lender Costs DiscountsRelatedToLenderCosts	0	USD
	ppch	Discounts Related To Lender Costs DiscountsRelatedToLenderCosts	48500	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-20644	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	83789	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5322	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	8725	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	17531	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	122728	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	87818	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-137667	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-918	USD
	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	-5	USD
	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	0	USD
	ppch	Related Party Expenses Paid On Behalf Of Company RelatedPartyExpensesPaidOnBehalfOfCompany	67760	USD
	ppch	Related Party Expenses Paid On Behalf Of Company RelatedPartyExpensesPaidOnBehalfOfCompany	0	USD
	us-gaap	Payments For Loans PaymentsForLoans	45511	USD
	us-gaap	Payments For Loans PaymentsForLoans	20000	USD
	us-gaap	Proceeds From Loans ProceedsFromLoans	10542	USD
	us-gaap	Proceeds From Loans ProceedsFromLoans	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	103959	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	675500	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	136745	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	684500	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	962	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	94508	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	40	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	80549	USD
CY2013Q2	us-gaap	Cash Cash	0	USD
CY2015Q1	us-gaap	Expense Related To Distribution Or Servicing And Underwriting Fees ExpenseRelatedToDistributionOrServicingAndUnderwritingFees	5000	USD
CY2015Q1	ppch	Net Proceeds From Notes Issued NetProceedsFromNotesIssued	34721	USD
	ppch	Issuance Of Preferred Stock For Services IssuanceOfPreferredStockForServices	0	USD
	ppch	Issuance Of Preferred Stock For Services IssuanceOfPreferredStockForServices	1067	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	9388	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	15041	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	918	USD
	ppch	Prepaid Common Stock Issued For Services PrepaidCommonStockIssuedForServices	6667	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	29000	USD
	ppch	Settlement Fees Paid In Form Of Debt SettlementFeesPaidInFormOfDebt	0	USD
	ppch	Settlement Fees Paid In Form Of Debt SettlementFeesPaidInFormOfDebt	150000	USD
CY2014Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	10000000	shares
CY2014Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	3000000	shares
CY2014Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.008
CY2014Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	80000	USD
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	72967	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	808	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
	ppch	Amortization Of Prepaid Shares Issued For Services AmortizationOfPrepaidSharesIssuedForServices	6667	USD
	ppch	Amortization Of Prepaid Shares Issued For Services AmortizationOfPrepaidSharesIssuedForServices	0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-77661	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	152285	USD
CY2015Q1	ppch	Increase In Liability Part Of Settlement Agreement IncreaseInLiabilityPartOfSettlementAgreement	44000	USD
CY2015Q1	us-gaap	Other Liabilities OtherLiabilities	575000	USD
CY2015Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	50000	USD
CY2015Q1	us-gaap	Noninterest Expense Transfer Agent And Custodian Fees NoninterestExpenseTransferAgentAndCustodianFees	7779	USD
CY2015Q1	us-gaap	Legal Fees LegalFees	2500	USD

Files In Submission

Name	View Source	Status
0001144204-15-031499-index-headers.html	Edgar Link	pending
0001144204-15-031499-index.html	Edgar Link	pending
0001144204-15-031499.txt	Edgar Link	pending
0001144204-15-031499-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ppch-20150331.xml	Edgar Link	completed
ppch-20150331.xsd	Edgar Link	pending
ppch-20150331_cal.xml	Edgar Link	unprocessable
ppch-20150331_def.xml	Edgar Link	unprocessable
ppch-20150331_lab.xml	Edgar Link	unprocessable
ppch-20150331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v410535_10q.htm	Edgar Link	pending
v410535_ex31-1.htm	Edgar Link	pending
v410535_ex31-2.htm	Edgar Link	pending
v410535_ex32-1.htm	Edgar Link	pending
v410535_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PPCB
Propanc Biopharma Inc Stock $ppcb

2015 Q2 Form 10-Q Financial Statement

#000114420415031499 Filed on May 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PPCB Propanc Biopharma Inc Stock $ppcb

2015 Q2 Form 10-Q Financial Statement

#000114420415031499 Filed on May 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PPCB
Propanc Biopharma Inc Stock $ppcb